Evidence record 11231 · automatically gathered

Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma

Chai Discovery Inc., a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3.8 billion. Index Ventures led the Series C round alongside Kleiner Perkins, Sequoia Capital and Dimension. New investors joining the investment included Bain Capital […] The post Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma appeared first on

Record details

Published: 14 July 2026
Source: SiliconANGLE AI
Category: News
Topics: Finance, VC & PE · Biotech
Retrieved: 17 July 2026

source-onlyevidence status

These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.

How to cite this record

ethics.ai (14 July 2026), “Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma,” evidence record 11231, https://ethics.ai/record/11231 (originally published by SiliconANGLE AI).

JSON

Use and limitations

This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.